How can onchocerciasis elimination in Africa be accelerated? Modeling the impact of increased ivermectin treatment frequency and complementary vector control by Verver, S. (Suzanne) et al.
Clinical Infectious Diseases
Modeling Onchocerciasis Strategies • CID 2018:66 (Suppl 4) • S267
Clinical Infectious Diseases®  2018;66(S4):S267–74
How Can Onchocerciasis Elimination in Africa Be 
Accelerated? Modeling the Impact of Increased Ivermectin 
Treatment Frequency and Complementary Vector Control
Suzanne Verver,1 Martin Walker,2,3 Young Eun Kim,1,4,a Grace Fobi,5 Afework H. Tekle,6 Honorat G. M. Zouré,6 Samuel Wanji,7 Daniel A. Boakye,8  
Annette C. Kuesel,9 Sake J. de Vlas,1 Michel Boussinesq,10 Maria-Gloria Basáñez,3 and Wilma A. Stolk1
1Department of Public Health, Erasmus MC, University Medical Center Rotterdam, The Netherlands; 2Department of Pathobiology and Population Sciences and London Centre for Neglected 
Tropical Disease Research, Royal Veterinary College, Hatfield, and 3Department of Infectious Disease Epidemiology and London Centre for Neglected Tropical Disease Research, Imperial College 
London, United Kingdom; 4Swiss Tropical and Public Health, Basel, Switzerland; 5Independent Consultant, Yaoundé, Cameroon; 6World Health Organization, Geneva, Switzerland; 7Department 
of Microbiology and Parasitology, Faculty of Science, University of Buea, Cameroon; 8Noguchi Memorial Institute of Medical Research, University of Ghana, Legon; 9United Nations Children’s 
Fund/United Nations Development Programme/World Bank/World Health Organization Special Programme for Research and Training in Tropical Diseases, Geneva, Switzerland; and 10Institut de 
Recherche pour le Développement, Montpellier, France
Background. Great strides have been made toward onchocerciasis elimination by mass drug administration (MDA) of ivermec-
tin. Focusing on MDA-eligible areas, we investigated where the elimination goal can be achieved by 2025 by continuation of current 
practice (annual MDA with ivermectin) and where intensification or additional vector control is required. We did not consider areas 
hypoendemic for onchocerciasis with loiasis coendemicity where MDA is contraindicated.
Methods. We used 2 previously published mathematical models, ONCHOSIM and EPIONCHO, to simulate future trends in 
microfilarial prevalence for 80 different settings (defined by precontrol endemicity and past MDA frequency and coverage) under 
different future treatment scenarios (annual, biannual, or quarterly MDA with different treatment coverage through 2025, with or 
without vector control strategies), assessing for each strategy whether it eventually leads to elimination.
Results. Areas with 40%–50% precontrol microfilarial prevalence and ≥10 years of annual MDA may achieve elimination with 
a further 7 years of annual MDA, if not achieved already, according to both models. For most areas with 70%–80% precontrol prev-
alence, ONCHOSIM predicts that either annual or biannual MDA is sufficient to achieve elimination by 2025, whereas EPIONCHO 
predicts that elimination will not be achieved even with complementary vector control.
Conclusions. Whether elimination will be reached by 2025 depends on precontrol endemicity, control history, and strategies 
chosen from now until 2025. Biannual or quarterly MDA will accelerate progress toward elimination but cannot guarantee it by 2025 
in high-endemicity areas. Long-term concomitant MDA and vector control for high-endemicity areas might be useful.
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Onchocerciasis (river blindness), caused by the filarial nema-
tode Onchocerca volvulus and transmitted by Simulium black-
flies, occurs in many rural areas of sub-Saharan Africa. It can 
cause skin problems (itch, skin depigmentation, premature 
atrophy), visual impairment, and blindness, and is also asso-
ciated with excess human mortality [1, 2] and possibly with 
epilepsy and nodding syndrome [2–4]. Despite large-scale, 
long-term control programs, the number of people infected in 
2016 was still estimated at 15 million [5].
Control in Africa was initially based on vector control (VC) (the 
Onchocerciasis Control Programme in West Africa, 1974–2002), 
before community-wide mass drug administration (MDA) of 
ivermectin became the principal intervention. Ivermectin has 
some activity against adult worms [6], but predominantly reduces 
skin microfilarial loads through its microfilaricidal and embry-
ostatic effects, thereby reducing symptoms and transmission [7]. 
When delivered annually, microfilarial prevalence declines slowly 
over time. For a long time, elimination of onchocerciasis through 
MDA was deemed impossible in Africa and therefore the African 
Programme for Onchocerciasis Control (APOC, 1995–2015) 
was defined as a morbidity control program [8]. In recent years, 
several African studies have indicated that elimination may be 
feasible by MDA, provided that sufficiently high and prolonged 
ivermectin treatment coverage is sustained [9–12].
The World Health Organization (WHO) now targets oncho-
cerciasis elimination in selected African countries by 2020, 
and which APOC deemed achievable, and in the majority of 
African countries by 2025 [13, 14]. However, it is now recog-
nized that annual MDA is unlikely to be sufficient to achieve 
these targets, and before its closure APOC proposed several 
“alternative treatment strategies” to accelerate elimination [15]. 
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These include MDA at higher frequency and complementary 
VC through localized ground-based larviciding at Simulium 
breeding sites [15].
The relative impact of different alternative treatment strate-
gies is uncertain. While controlled studies to compare different 
treatment strategies are not feasible, mathematical modeling can 
provide critical information for policy decisions. Two different 
models, ONCHOSIM and EPIONCHO [16], are in use to sup-
port policy making for onchocerciasis elimination programs [12, 
17–27]. We used both models to simulate future trends in micro-
filarial prevalence and to assess whether elimination occurs under 
different future intervention strategies, including annual, biannual 
(ie, every 6 months), and quarterly (ie, every 3 months) MDA with 
ivermectin through 2025, with or without complementary VC. 
This is done for different settings defined by precontrol endem-
icity and MDA history, selected to reflect heterogeneity among the 
majority of endemic areas in APOC countries.
METHODS
Mathematical Models
Technical details for ONCHOSIM and EPIONCHO, refer-
ences, and model comparison can be found in [16, 21, 22]. 
The parameter values used for EPIONCHO are the best com-
binations reported in Walker et al [22] from a full exploration 
of the parameter space. Supplementary Tables 2 and 3 of the 
Supplementary Materials list parameters for ONCHOSIM and 
EPIONCHO, respectively.
ONCHOSIM is an individual-based stochastic model, simu-
lating transmission of onchocerciasis in a dynamic population 
of approximately 400 persons, representing a typical endemic 
village. The model “tracks” the life histories of individual male 
and female adult and populations of microfilariae within indi-
vidual human hosts. Parasite transmission by a population of 
blackflies with the 3 larval (L1, L2, L3) stages within the vector 
is modeled deterministically, with seasonal variation in trans-
mission defined by monthly biting rates (number of bites per 
person per month). The model accounts for age- and sex-de-
pendent heterogeneity in exposure to blackfly bites and treat-
ment compliance, with a flexible structure to model realistic 
distributions of adult worm lifespans [18, 28, 29].
EPIONCHO is a deterministic population-based transmis-
sion model that uses partial differential equations to describe 
changes with respect to time and host age in mean numbers 
of female adult worms per human host, microfilariae per mil-
ligram of skin, and (L1, L2, L3) larvae per blackfly [1, 16, 22]. 
EPIONCHO is based on a prototype presented in [30], extended 
to include age and sex structure of the human population [31] 
and temporal dynamics of microfilariae following ivermectin 
treatment [7]. The model incorporates age- and sex-specific 
patterns of exposure to blackfly bites [31] and the net effect on 
transmission of individual heterogeneity in exposure.
In both models, precontrol microfilarial prevalence levels are 
calibrated by adjusting the annual biting rates [16, 21, 22].
Responses to ivermectin treatment are modeled in a sim-
ilar fashion in both models. In EPIONCHO, ivermectin is 
assumed to kill 98%–99% of microfilariae 1–2  months after 
treatment, to sterilize adult female worms temporarily, and 
to reduce cumulatively their capacity to produce microfilar-
iae [7, 17]. In ONCHOSIM, 100% of microfilariae are killed 
instantaneously by treatment. Rates at which female worms 
resume microfilarial production are subtly different between 
the 2 models [16, 21, 32]. Both models assume that children 
<5  years of age are excluded and that 5% of the remaining 
population never participates in MDA (ie, systematic non-
adherers) [33]. EPIONCHO partitions the population into 4 
treatment groups: a full adherence group that takes treatment 
every round; 2 semiadherent groups that take treatment every 
other round alternately; and a systematically nonadherent 
group that never takes treatment. In ONCHOSIM, participa-
tion of individuals in MDA rounds is driven by a probability 
that depends on age and sex, and a parameter governing a per-
sonal inclination to adhere to MDA.
Simulated Settings and Treatment Scenarios
Simulations were done for 80 different settings, defined by the 
assumed precontrol endemicity level (precontrol microfilarial 
prevalence in ≥5-year-olds of 40%, 50%, 60%, 70%, or 80%) 
and history of control (0, 5, 10, 15, or 20 years of annual MDA 
or 5  years of biannual MDA, with coverage of 50%, 65%, or 
80%), to capture a large fraction of the heterogeneity across 
African endemic areas. Settings were assumed to be eligible for 
MDA (low-endemic onchocerciasis areas with loiasis coende-
micity are therefore not considered; these areas require alter-
native interventions). For each setting, we evaluated whether 
continuation of MDA was needed for elimination and whether 
elimination could be achieved within 7  years by continuing 
current practice of annual MDA or switching to one of the 
alternative treatment strategies (Table  1), with or without 
complementary VC.
The 7-year MDA duration (2019–2025) was chosen to 
align with the 2025 elimination target year and the prepara-
tion period required to implement a change in MDA strategy. 
Complementary VC was assumed to be implemented locally 
by regular (weekly or monthly) ground larviciding of blackfly 
breeding sites [34, 35]. This may require a longer preparation 
period, for identification of breeding sites and Simulium spe-
cies, determination of larvicide efficacy and optimal dosage, 
and so forth [34]. Therefore, the start of VC was assumed to 
begin in 2021. We considered different durations of VC: 5 years 
(assuming that VC stops in 2025, the same stop year as MDA) 
or 15 years (ie, spanning the estimated average reproductive life 
span of adult worms). The effect of VC was modeled as a con-
stant 70% reduction in biting rates [35].
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Identification of Preferred Strategy
We identified the preferred strategy to achieve elimination by 
2025 for each model. When the models predicted that ≥2 strat-
egies could lead to elimination, the more feasible strategies 
were given preference: (1) Annual MDA with higher cover-
age was preferred to biannual or quarterly MDA with lower 
coverage; and (2) strategies with shorter VC were preferred 
to strategies with longer VC (except in cases when quarterly 
MDA was indicated; scenarios with annual or biannual MDA 
plus VC were given as equal alternatives to quarterly MDA). 
For settings with a history of control, we did not consider a 
reduction in treatment frequency (from biannual to annual) 
or coverage.
Simulations and Analysis
The stochasticity in ONCHOSIM means that repeated simula-
tions for the same scenario give slightly different results, some-
times ending in elimination and sometimes in recrudescence. 
Therefore, each scenario was run 1000 times, and we calculated 
the average microfilarial prevalence and the percentage of simu-
lation runs resulting eventually in zero microfilarial prevalence. 
Elimination was said to occur if ≥99% of simulations resulted in 
zero microfilarial prevalence 50 years after cessation of MDA. 
The 50-year time horizon permitted robust assessment of 
whether the parasite population became extinct or recrudesced 
because worm and microfilarial prevalence do not necessarily 
have to be zero when interventions are stopped.
For EPIONCHO, a single (deterministic) simulation was run 
for each scenario to determine the average trend in microfilar-
ial prevalence over time and to identify whether elimination 
was reached 50 years after cessation of MDA. Elimination was 
considered achieved if the mean number of all parasite stages 
tended terminally to zero. This determines numerically whether 
the transmission breakpoint had been crossed [22].
RESULTS
Figure 1 shows predicted trends in microfilarial prevalence for 
selected settings and treatment scenarios for both models dur-
ing interventions. Prospects for achieving elimination by 2025 
strongly depend on precontrol endemicity level (Figure  1A) 
and history of control (Figure 1B). Both factors determine the 
model-predicted residual microfilarial prevalence that remains 
now in 2017 and after stopping MDA in 2025. The greatest 
reductions in microfilarial prevalence are achieved when MDA 
coverage is high or treatment is given frequently (Figure 1C), 
whereas adding VC during MDA has little impact on micro-
filarial prevalence dynamics (Figure 1D, compare dashed and 
solid lines). Continuation of VC after cessation of MDA, how-
ever, can help to prevent recrudescence after cessation of MDA.
Figure 1 also shows that the 2 models give very different pre-
dictions. In Figure  1A, for example, ONCHOSIM predicts a 
decline in microfilarial prevalence to <5% even in high-precon-
trol-prevalence settings, whereas the EPIONCHO-predicted 
decline is much lower and the modest reduction in prevalence 
in high-endemicity settings leads to fast recrudescence after 
stopping annual MDA in 2025.
Table  2 identifies for each model the preferred strategy 
to achieve elimination after stopping MDA in 2025. This fig-
ure clearly shows that more efforts are needed in settings with 
higher precontrol prevalence or a shorter or less intensive his-
tory of control. Some of the settings with a history of ≥10 years 
of MDA are predicted to have achieved the elimination tar-
get already, and the model preferred strategy for such settings is 
to proceed to evaluation (continuing the current strategy until 
that time, ensuring high coverage and preventing systematic 
nonadherence).
For most low-endemic settings (40%–50% precontrol microfi-
larial prevalence), both models predict that the 2025 elimination 
Table 1. Elements of Future Treatment Strategies
Type Strategy Code Explanation Remarks
Future MDA A65, A80 7 y of aMDA with ivermectin, starting in 2019 with the last treatment 
given in 2025, covering 50%, 65%, or 80% of the population, re-
spectively. aMDA is provided in month 6, just before peak transmis-
sion season.
aMDA is not considered in settings with a 
history of bMDA; for settings with a his-
tory of control, we do not consider strat-
egies involving a reduction in coverage or 
treatment frequency.
B65, B80 As above, but with bMDA. Treatment is provided in months 6 and 12 
(14 treatment rounds over 7 y).
Q65, Q80 As above, but with quarterly MDA. Treatment is provided in months 3, 
6, 9, and 12 (28 treatment rounds).
Future VC VC5, VC15 VC through ground-based larviciding, continued for 5 or 15 y, respec-
tively. VC starts 2 y later than future MDA (from January 2021 
onward) to allow for necessary preparations; VC ends in the same 
year as MDA if continued for only 5 y, and 10 y later with the 15-y 
duration.
Evaluation E Elimination is predicted to have been achieved with the current strat-
egy used to 2018; evaluation should be scheduled, and until then, 
the current strategy should be continued (with at least 65% treat-
ment coverage).
Only considered in settings with a history 
of annual or bMDA, to check whether ad-
ditional interventions are needed at all.
Abbreviations: aMDA, annual mass drug administration; bMDA, biannual mass drug administration; MDA, mass drug administration; VC, vector control.
D
ow
nloaded from
 https://academ
ic.oup.com
/cid/article-abstract/66/suppl_4/S267/5020619 by Erasm
us U
niversiteit R
otterdam
 user on 18 D
ecem
ber 2018
S270 • CID 2018:66 (Suppl 4) • Verver et al
target can be achieved by continuing the current strategy of 
annual MDA, if not achieved already. Only few of these settings 
are predicted to require an increase in coverage or treatment fre-
quency (more often with EPIONCHO than with ONCHOSIM).
The predictions for settings with ≥60% precontrol prevalence 
vary strongly between models. ONCHOSIM suggests that elim-
ination is achievable in most settings with MDA alone, although 
this might require an increase in treatment frequency or cover-
age. Only in settings with 80% precontrol microfilarial preva-
lence and no or only 5 years of past MDA, quarterly treatment 
or addition of VC would be needed. EPIONCHO, however, 
suggests that such intensive strategies are already required 
in settings with 60% precontrol prevalence, and predicts that 
elimination cannot be achieved with 7 years of MDA with any 
of the strategies examined in settings with ≥70% microfilarial 
prevalence.
Detailed simulation results by setting (defined by precontrol 
microfilarial prevalence and history of control), showing the 
trends under the various alternative treatment strategies, are 
shown for each model in the Supplementary Materials.
Figure 1. Illustrative predicted trends in onchocerciasis microfilarial prevalence in different settings of endemicity with different past and future interventions. For full set 
of graphs, see Supplementary Data 2 and 3. Microfilarial prevalence projected by ONHCOSIM represents the mean per 1000 model runs. The projections are deterministic 
for EPIONCHO. Labeled future intervention strategies were simulated from 2019 to 2025 (vector control 15 years has vector control but not mass drug administration applied 
until 2035). A, Precontrol (baseline) microfilarial prevalence. B–D, 60% precontrol microfilarial prevalence. D, No history of control. Abbreviations: aMDA, annual mass drug 
administration; cov., coverage; fut. tr., future treatment; MDA, mass drug administration; mf, microfilariae; prev. = prevalence.
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DISCUSSION
We show that precontrol endemicity levels (microfilarial preva-
lence) and control histories (when MDA began and how effect-
ively it was implemented) drive the intervention strategies 
needed for onchocerciasis elimination by 2025 or thereafter. For 
many low-endemic settings (40%–50% precontrol microfilar-
ial prevalence), continuation of the current strategy of annual 
MDA may be sufficient to achieve elimination by 2025 if not 
achieved already. By contrast, many settings with higher pre-
control levels may need an intensified MDA strategy (increase 
in coverage, increase in frequency) and sometimes complemen-
tary VC, particularly those with a short history of control.
Uncertainty
In general, ONCHOSIM’s predictions regarding elimination 
prospects are much more optimistic than EPIONCHO’s, 
which accords with our previous model comparison study 
[18], and remained after revision of the EPIONCHO model 
[22]. We have identified many factors that contribute to the 
difference. Differences in microfilarial prevalence dynamics 
during the intervention are strongly influenced by the differ-
ent assumptions made by the models on the sensitivity of the 
skin snip. ONCHOSIM assumes a random (Poisson) distribu-
tion of microfilariae within the skin, implying high sensitivity, 
whereas EPIONCHO models an aggregated or patchy (negative 
binomial) distribution, implying low sensitivity, especially in 
low-intensity infections [36]. The models also differ in their rep-
resentation of the relationship between microfilarial prevalence 
and vector biting rate. In EPIONCHO, high precontrol micro-
filarial prevalence is associated with a much greater underlying 
intensity of transmission (vector biting rate) than ONCHOSIM 
[22], making elimination more difficult to achieve. Moreover, 
ONCHOSIM considers transmission dynamics in a single com-
munity of about 400 individuals and chance elimination by 
stochastic processes may frequently occur, whereas the pop-
ulation-based EPIONCHO implicitly represents a very large 
population, which helps to stabilize transmission (and does not 
include stochastic/chance elimination). Moreover, EPIONCHO 
takes account of several density-dependent processes, which are 
not considered in ONCHOSIM, that enhance the efficiency of 
transmission when parasite intensity in the population becomes 
low. Elimination in ONCHOSIM is accelerated by the assump-
tion that older worms produce fewer microfilariae than young 
worms [37], which is not considered in EPIONCHO. Moreover, 
neither model includes external forces of infection from neigh-
boring communities. In reality, infection dynamics will be 
influenced by movement of infected humans, flies, or changes 
in demographic, geographic, and environmental conditions. 
Table  2. Strategies Predicted to Achieve Onchocerciasis Elimination: Preferred Strategy Required From 2019 With Maximum 7 Years of Mass Drug 
Administration to Achieve Elimination of Onchocerciasis as Predicted by the Transmission Models ONCHOSIM and EPIONCHO
History of MDA
ONCHOSIM Predictions EPIONCHO Predictions
Precontrol mf Prevalence in  
Population Aged ≥5 y
Precontrol mf Prevalence in  
Population Aged ≥5 y
Years Frequency
Past Treatment 
Coverage 40% 50% 60% 70% 80% 40% 50% 60% ≥70%
0 … … A65 A80 A80 B80 A65 + VC15 / Q65 A65 B65
Not possible with strategies 
considered
5 A 50% A65 A65 A65 A80 B65 + VC5 / Q65 A65 A65 Q65 + VC15
10 A 50% E* A65 A65 A65 B65 E* A65 B65 + VC15
15 A 50% E* E* E* A65 A80 E* E* B65
20 A 50% E* E* E* E* A65 E* E* A65
5 A 65% A65 A65 A65 A80 B80/Q65 A65 A65 Q65 + VC15
10 A 65% E E E A65 A80 E A65 A80 + VC15
15 A 65% E E E E A65 E E A80
20 A 65% E E E E E E E A65
5 A 80% E A80 A80 A80 B80 A80 A80 Q65 + VC15
10 A 80% E E E E A80 E E A80 + VC15 / Q80
15 A 80% E E E E E E E A80
20 A 80% E E E E E E E A80
5 B 50% B65 B65 B65 B65 B80 E B65 B65 + VC15
5 B 65% E E B65 B65 B65 E B65 B65 + VC15
5 B 80% E E E B80 B80 E B80 B65 + VC15
Rows indicate the history of MDA. The colors indicate which strategy is needed; the darker the color, the more intense are the required efforts. Strategies separated by a dash indicate that 
both alternatives are predicted to lead to elimination. Elimination is predicted to have been achieved with the strategy used to 2018; evaluation should be scheduled and, until then, the 
current strategy should be continued.
Abbreviations: A, annual mass drug administration; B, biannual mass drug administration; E, elimination; mf, microfilariae; Q, quarterly mass drug administration; VC5, vector control for 
5 years; VC15, vector control for 15 years.
*Treatment coverage should be at least 65% as this is standard recommendation.
D
ow
nloaded from
 https://academ
ic.oup.com
/cid/article-abstract/66/suppl_4/S267/5020619 by Erasm
us U
niversiteit R
otterdam
 user on 18 D
ecem
ber 2018
S272 • CID 2018:66 (Suppl 4) • Verver et al
Some of the factors highlighted above could make ONCHOSIM 
too optimistic or EPIONCHO too pessimistic. The ranges pre-
sented in Table 2 give a good indication of real uncertainties, 
and the truth may lie between the predictions of these 2 models.
Choosing a Strategy
Our work may help onchocerciasis elimination programs to 
choose the most appropriate intervention strategy to achieve 
the time-bounded elimination targets. Within a treatment 
area, there is usually variation among community endemicities, 
achieved coverage, and the fraction of the population that never 
participates in mass treatment. Programs should ideally choose 
a strategy that is sufficient to achieve the elimination target in 
all settings within the larger area. Yet, the choice is often driven 
by other factors, including logistical feasibility, budgetary, and 
resource constraints. We have based the selection of strategies 
in Table  2 on the likely ease of implementation, but not on 
cost-effectiveness analyses. Previous modeling has shown that 
treating biannually or even quarterly, although increasing the 
total number of treatment rounds compared to annual MDA 
[21], can achieve cost-savings by shortening program duration, 
particularly in highly endemic settings [27].
We have shown that localized VC can sometimes help to 
achieve elimination targets or can help to maintain the gains after 
cessation of MDA, especially in very highly endemic areas. It may 
also be an attractive option to control the nuisance from biting 
blackflies. In practice, VC through larviciding might be imple-
mented just before and during the blackfly breeding season. More 
research on the feasibility and cost-effectiveness of ground-based 
larviciding is needed, as are submodels that more accurately 
reflect the effect of larviciding on blackfly population dynamics.
Evaluation
Implementation of a selected strategy does not guarantee suc-
cess, due to uncertainty about local endemicity, past and future 
(therapeutic) coverage patterns, and geographic coverage. If 
MDA coverage is lower or the fraction of systematic nonadh-
erers higher than assumed in our simulations, the effectiveness 
of interventions will likely deviate from the model predictions 
[33]. Decisions to stop intervention activities need to be based 
on field evaluations including transmission assessment (meas-
uring infection or past exposure in humans and blackflies) 
across intervention areas, to test whether residual infection lev-
els in human and blackfly infectivity are below thresholds asso-
ciated with minimal risk of recrudescence.
Residual onchocerciasis infection may persist for some time, 
even when elimination may ultimately be achieved. Some strate-
gies that lead to elimination 50 years after stopping MDA are asso-
ciated with relatively high microfilarial prevalence (~10%) 1 year 
after the last MDA round (Figure  1, rows 3 and 4). Modeling 
studies indicate that previously highly endemic areas should aim 
for less residual infection than precontrol low-endemic areas 
[37]. Exact thresholds need to be determined [38, 39], in particu-
lar for infective blackflies and the new serologically based expos-
ure assessment tools recommended by the WHO [40].
Feasibility of Elimination by 2025
We chose to model MDA only until 2025 as targets were set 
for this year [13]. Our predictions suggest that this may not 
always be achievable, or could require intensification of inter-
vention efforts. Hence, elimination targets may need adjust-
ment to make them more attainable. Most problematic are 
areas with high precontrol endemicity and those with no or 
only short histories of control. Whereas most areas where con-
trol has not yet started are low endemic [15], there are some 
highly endemic areas where interventions began only recently 
(eg, Democratic Republic of Congo, Central African Republic, 
and South Sudan) [41]. We did not include areas with very high 
community microfilarial loads associated with a microfilarial 
prevalence exceeding 80% or even 90%, as the models are chal-
lenged by such extreme situations.
We did not investigate feasibility of elimination in areas low 
endemic for onchocerciasis and coendemic for loiasis, where 
current MDA strategies cannot be used, because of an unaccept-
ably high risk of serious adverse events. This is a problem for 
many countries in the Central African region, including Angola, 
Cameroon, Central African Republic, Chad, Congo, Democratic 
Republic of Congo, Equatorial Guinea, Gabon, Nigeria, and 
South Sudan [42, 43]. Millions of people in these areas are there-
fore left untreated, presenting a source for reintroduction of 
onchocerciasis in previously eliminated areas. Alternative treat-
ment strategies are urgently needed, such as the test-and-not-
treat strategy [44]. This strategy seems to have similar impact as 
regular MDA when the same coverage can be achieved, which 
makes our results more generalizable. Modeling results for strat-
egies in these areas will be presented elsewhere.
Alternative treatment strategies required to eliminate oncho-
cerciasis have been identified by APOC [15, 45]. These include 
new drugs suitable for MDA, such as moxidectin [45, 46], which 
could significantly accelerate progress toward elimination, as 
our earlier modeling suggests [23]. Antibiotics targeting the 
Wolbachia endosymbionts of O. volvulus could be used within 
test-and-not-treat strategies [44], particularly in loaisis-coen-
demic areas because they are safe for coinfected patients [47]. 
Vaccines could have a substantial impact in a range of endem-
icity settings, and could markedly reduce host microfilarial 
loads in children and adolescents [24].
CONCLUSIONS
It will be challenging to achieve onchocerciasis elimination 
targets in Africa and, in some areas, the target date should be 
shifted to be more attainable. Onchocerciasis control and elim-
ination programs should aim for a high therapeutic coverage. 
Biannual treatment will be needed in hyperendemic settings 
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with few years of past MDA. In the most highly endemic areas, 
even quarterly MDA with ≥80% coverage, if feasible, may not 
achieve elimination by 2025. The feasibility of localized VC by 
ground-based larviciding should be considered as an adjunct to 
MDA in some settings [34].
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